Syndax Pharmaceutcals, Inc.

Syndax Pharmaceutcals, Inc.

Syndax is conducting clinical trials to assess the benefit of axatilimab (SNDX-6352) in treating chronic graft versus host disease (cGVHD). Axatilimab is a type of antibody that impacts cells called monocytes and macrophages. Interfering with these monocytes and macrophages may help reduce the inflammation and fibrosis patients with cGVHD experience. Syndax has initiated the AGAVE-201/NCT04710576 study to further explore safety and efficacy in patients with relapsed or refractory disease. 

Homepage: www.syndax.com    

Pipeline:  www.syndax.com/pipeline 

Axatilimab: syndax.com/pipeline/axatilimab 

Contact Information: 

Email: hqamoos@syndax.com